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 ABSTRACT  
Low energy and fatigue are frequent complaints in subjects with GH deficiency 
(GHD). Since interrelations between sleep and GH regulation are well documented, 
these complaints could partly reflect alterations of sleep quality.  Therefore we 
sought to determine objective and subjective sleep quality and daytime sleepiness in 
adult GHD patients compared to age, gender and BMI-matched controls, and in a 
subset of these GHD patients undergoing recombinant human GH (rhGH) therapy 
compared to placebo.  
Thirty patients, aged 19-74 yr, with untreated GHD (primary pituitary defects 
confirmed or likely in 26 patients, hypothalamic origin in 4 patients), and 30 
healthy controls individually matched for gender, age and body mass index were 
enrolled in the study. Patients with associated pituitary hormonal deficiencies were 
on appropriate replacement therapy. Polygraphic sleep recordings were performed 
at baseline and after 4 months on recombinant human GH or placebo. Subjective 
sleep quality and quality of life were evaluated by means of the Pittsburgh Sleep 
Quality Index (PSQI) and Quality of Life-Assessment for GHD in Adults (QoL-
AGHDA). Irrespective of etiology, GHD patients had a PSQI score above the 
clinical cut-off for poor sleep and lower QoL-AGHDA scores than controls, with 
tiredness being the most affected domain. Patients with pituitary GHD spent more 
time in slow-wave sleep (SWS) and had a higher intensity of SWS than their 
controls. Amongst these patients, older individuals obtained less total sleep than 
controls and their late sleep was more fragmented. Contrasting with pituitary GHD, 
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the 4 patients with hypothalamic GHD had lower intensity of SWS than their 
controls. Thirteen patients were reevaluated after 4 months rhGH and 4 months 
placebo. Compared to placebo, SWS duration was decreased in younger patients 
after rhGH, and a trend for a decrease in SWS intensity was observed in the whole 
group. PSQI scores decreased, while QoL ratings improved. In conclusion, GHD is 
associated with sleep disorders that may be caused by specific hormonal alterations, 
as well as with poor subjective sleep quality and daytime sleepiness. Disturbed 
sleep is likely to be partly responsible for increased tiredness, a major component of 
QoL in GHD. Partial reversal of the sleep alterations was observed after 4 months 
of rhGH treatment, which was paralleled by an improvement in QoL and reports of 
tiredness, as well as subjective sleep quality. 
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INTRODUCTION  
Growth hormone deficiency 
Growth hormone (GH) is secreted by the pituitary somatotrophs under the 
stimulatory influence of hypothalamic GH-releasing hormone (GHRH).  Acylated 
ghrelin, a peptide produced mainly by the stomach, is another potent endogenous 
GH secretagogue, but its contribution to the control of spontaneous GH secretion 
under physiological conditions has not been fully clarified yet 1-3. GH secretion is 
inhibited by somatostatin, and by negative feedback from IGF-I and GH itself. 
Recently, the orexin/hypocretin system, initially identified as a regulator of food 
intake, and subsequently as a key modulator of the sleep-wake cycle, was also 
implicated in the control of the somatotropic system 4-5. Finally, GH secretion is 
influenced by a variety of other metabolic, neural and hormonal factors (reviewed 
in 5). GH exerts a broad spectrum of effects, either directly or via the stimulation of 
the release of insulin-like growth factor-I (IGF-I) from the liver. These effects 
include the promotion of linear growth in children, and the regulation of 
carbohydrate, protein, lipid, and mineral metabolism throughout the lifetime.  
Adult GH deficiency (aGHD) was recognized as a distinct syndrome in the late 
1980s 6-8. While childhood-onset GHD is more frequently due to genetic causes or 
idiopathic, aGHD is usually a consequence of a pituitary or sellar insult (pituitary 
adenoma, craniopharyngioma, neurosarcoidosis) or their treatment (surgery, 
radiation therapy). Other, less frequent but increasingly recognized, causes of 
aGHD are traumatic brain injury, empty sella syndrome, and lymphocytic 
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hypophysitis. At variance with childhood-onset cases, in adults, GHD, because of 
its etiology, is frequently associated to other pituitary hormone deficiencies, while it 
is more frequently isolated in children 9-11  
Clinical picture 
From a clinical point of view, adults with GHD present with alterations of: 
Table 1: Clinical picture of the adult GH deficiency syndrome (NO nitric oxide, SMC smooth muscle 
cells, VO2max aerobic capacity). 
Body composition 12-14 ↑ subcutaneous fat 
↑ visceral fat 
↓ lean mass (trunk and limbs) 
Bone mass 12, 15 , 16 ↓ bone mineral density 
↓ markers of bone     turnover 
Lipid profile  12-13, 17 ↑ total cholesterol 
↑ LDL cholesterol 
↑ HDL cholesterol  
↑ or = triglycerides 
Glucose tolerance 18-19 Insulin-resistance 
Heart structure and function 12, 20 ↓ thickness of left ventricular posterior wall and 
interventricular septum 
↓ or = ejection fraction 
Impaired left atrium diastolic filling 
Endothelial function 20-21 ↓ endothelial production of NO 
Resistance of vascular SMC to NO 
↑ intima-media thickness 
↑ greater arteries rigidity 
↑  or = C-reactive protein 
Muscle strength and endurance to exercise 12, 22 ↓ isometric strength 




The diagnosis of GHD is based on the clinical history, clinical picture and 
provocative tests of somatotropic function 23-24. The gold standard is the insulin 
tolerance test (ITT) which investigates the integrity of the hypothalamic-pituitary 
axis. The glucagon test relies on a similar mechanism. Other tests, such as the 
combined GHRH+arginine test or the GHRH+growth hormone releasing peptide 
test, are based on the administration of compounds that maximally stimulate the GH 
secretory reserve of the pituitary.  The ITT can be contraindicated in patients with 
ischemic heart disease, seizures and elderly. In adults, one provocative test is 
usually sufficient to establish the presence of GHD. The cut-off for the diagnosis of 
GHD varies with the test used. For the ITT the validated cut-off for GHD in adults 
is a peak GH response of <3 mg/l 25. The following cut-off levels have been 
validated for GHRH+arginine: for those with a body mass index (BMI) <25 kg/m2, 
a peak GH <11 mg/l; for BMI between 25 and 30 kg/m2, a peak GH<8 mg/l; and for 
BMI >30 kg/m2, a peak GH<4 mg/l 26. Of note, the latest clinical practice 
guidelines published by the Endocrine Society 27 report the results of a study 
comparing 6 different provocative tests for the diagnosis of adult GHD, in which 
the cut-off for peak GH response to GHRH+arginine with highest sensitivity (95%) 
and specificity (91%) was found to be 4.1 mg/l 28. 
IGF-I is also an indicator of GH status; however, in adults, normal levels do not rule 
out GHD since only approximately 50% of middle-aged adults with severe GHD 
defined by GH tests have a pathologically low IGF-I level (below –2 SDS). IGF-I 
measurement, however, was proven to be a more sensitive marker of severe GHD in 
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young adults compared with middle-aged adults, being especially sensitive in young 
adults with childhood onset GHD 29. Attention must be paid to other factors that can 
influence IGF-I levels, such as obesity, malnutrition, hepatic diseases, 
hypothyroidism. In the appropriate clinical context, very low IGF-I levels are 
nevertheless considered indicative of severe GHD and do not require further 
investigation with provocative testing 23. 
 
Quality of life in adult GHD patients 
As more and more patients were evaluated, another significant aspect of the 
syndrome emerged: aGHD patients frequently complained of reduced quality of life 
(QoL), the most consistent complaints being related to energy levels, vitality, 
mental fatigue and emotional reactions, as well as social isolation, anxiety, reduced 
self-confidence, dissatisfaction with body image and poor memory 30. In 1999 a 
specific questionnaire was developed, based on interviews with patients from 5 
different European countries (United Kingdom, Germany, Italy, Spain, Sweden). 
The interviews investigated the following topics: work, household chores, sleep, 
hobbies, leisure time pursuits, family life, intimate relationships, sex, memory and 
concentration, mood, energy, body image, self confidence and self-esteem, social 
activities, friendships, expectations and hopes. Twenty-five statements were 
selected that best described issues experienced by patients. The possible answers 
were yes or no, and scores ranged from 0 (best) to 25 (worst) 31. This questionnaire, 
called “Quality of Life Assessment of Growth Hormone Deficiency in Adults” 
(QoL-AGHDA) was validated against previously available, generic, quality of life 
 9
questionnaires, and in several languages, and subsequently used in several clinical 
studies evaluating the effect of recombinant human GH (rhGH) treatment. Murray 
et al. 32 studied 65 patients with aGHD at baseline, and after 3 and 8 months of 
rhGH treatment, and reported a significant improvement of QoL scores during 
treatment, particularly in males. A significant correlation was demonstrated 
between the impairment of QoL at baseline and its improvement during rhGH 
therapy. Similar results were obtained by other authors in patients on rhGH for up 
to 8 years 33-38; most authors observed a greater improvement in the first year of 
follow-up, but the improvement was sustained in the following years. Koltowska-
Haggstrom et al. 37, using data from the KIMS database, reported that QoL scores, 
after long-term rhGH treatment, approximated those of the general population, in 4 
different European countries. Normalization of QoL as determined by using the 
QoL-AGHDA questionnaire was also observed by the same group in German 
patients after 12 months treatment 38. Conversely, Malik et al.39 compared QoL 
scores of 89 aGHD patients on rhGH treatment for an average of 3 years with those 
obtained from 83 age- and gender-matched healthy control subjects from the 
general population, and reported significantly higher scores in patients despite 
therapy. These conflicting results could be linked to the different duration of 
follow-up, etiology of GHD, and scores obtained in the general population 37. There 
also appears to be a chronology in the improvement of the different dimensions 
explored by the questionnaire, the least affected (socializing issues) improving 
earlier than the most affected (tiredness, memory and concentration) 37. Maiter et al. 
40 looked at the impact of previous radiation therapy and found that the 
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improvement in QoL scores was similar in irradiated and non-irradiated aGHD 
patients. 
   
Sleep  
Sleep is divided into two distinct states of brain activity which are defined based on 
the appearance of specific features in the electroencephalogram (EEG), the 
electrooculogram and the electromyogram: rapid eye movement (REM) sleep, 
characterized by mixed low-amplitude high frequency EEG activity, muscle atonia 
and rapid eye movements, and non-REM (NREM) sleep.  During the deeper stages 
of NREM sleep, EEG frequency becomes progressively slower and well-defined 
high amplitude slow waves appear (Fig. 1).  
Fig. 1: brain waves recorded by EEG during relaxed wakefulness and sleep. 
 
NREM sleep and REM sleep alternate cyclically, with a periodicity of about 90 
minutes, and a typical night comprises 4 to 6 of such NREM-REM cycles (Fig. 2). 
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NREM sleep is more prevalent in the first half the night, while REM sleep episodes 
are more represented in the second half. NREM sleep is subdivided into four stages: 
I, II, III, IV; stages III and IV are also called slow-wave sleep (SWS) because of the 
prevalence of low frequency, high-amplitude “delta” waves 41. In young people, 
SWS represents about 20% of sleep duration, stages I and II about 50% and REM 
about 25%. Older individuals display an increased number and duration of 
awakenings and decreased amounts of SWS, while REM sleep appears to be 
relatively preserved 42. 
 
Fig. 2: Hypnogram of a typical night recorded in a young subject. 
 
 
The timing, duration and quality of sleep during any given 24-hour period 
ultimately results from the activity of two interacting time-keeping mechanisms in 
the central nervous system: endogenous circadian rhythmicity and sleep-wake 
homeostasis; the former is generated by a feedback loop of gene 
transcription/translation in the suprachiasmatic nuclei of the hypothalamus that 
results in a self-sustained near 24-hour oscillation, while the latter relates the timing 
and intensity of sleep to the duration of prior wakefulness 43-45. 
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Neurophysiological basis of sleep 
From a neurophysiological point of view, normal waking is associated with 
neuronal activity in several chemically defined ascending arousal systems, 
including monoaminergic neurons in the brainstem and posterior hypothalamus, 
cholinergic neurons in the brainstem and basal forebrain, and hypocretin (orexin) 
neurons in the lateral hypothalamus. The activity of these neuronal populations is 
reflected in the low-voltage fast-frequency EEG pattern of wakefulness, and 
declines rapidly at sleep onset 46. Non-rapid eye movement (NREM) sleep is 
generated by neurons located in the preoptic region of the hypothalamus and 
adjacent basal forebrain. These so-called “sleep-active neurons” have been shown 
to be gamma-aminobutyric acid (GABA)-ergic neurons which have direct 
projections to the “wake-active” areas and most likely inhibit them by releasing 
GABA 47, resulting in a progressive slowing of EEG frequencies. When the firing 
activity of the sleep-active neurons is synchronized, delta (slow) waves, which are 
considered a marker of sleep depth, appear on the EEG. Finally, REM sleep is 
generated by the activation of neurons in the pons and adjacent portions of the 
midbrain 46-47. 
 
Power spectral analysis of the EEG 
Power spectral analysis, a methodology that describes how the power of a signal or 
time series is distributed across frequencies is used to further characterize sleep and 
gives information about the quality of sleep. It is based on the assumption that the 
EEG can be mathematically decomposed into an infinite number of pure sinusoidal 
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components, each of a different frequency, which when added together yield the 
original signal. Applying a Fast Fourier Transform to the EEG signal allows to 
obtain an approximation of these frequency components separately 48. The most 
investigated frequency band is the delta band (0.75-4 Hz), which reflects the low-
frequency waves typically observed in SWS. Delta power is normally highest at the 
beginning of the sleep period and subsequently decreases throughout the night 44, 
49. Delta power, also referred to as “slow-wave activity” (SWA), is considered as a 
marker of sleep pressure 43, 49-50 and is highly reproducible in the same individual 51-
52, although it decreases with age 53. The other frequency bands are theta (4-7 Hz), 
alpha (7-12 Hz), sigma (12-15 Hz), beta (15-30 Hz) and gamma (>30 Hz). Sigma 
power is generated by the occurrence of sleep spindles, alpha power is a marker of 
the synchronization of cortical oscillations in high frequency ranges, and beta and 
gamma power reflect intra-sleep arousal. 
 
Relationships between the somatotropic axis and sleep  
GH secretion and sleep 
In healthy young men, the major GH secretory episode occurs after sleep onset, and 
may account for as much as 70% of the total 24-hr GH secretion.  Daytime GH 
levels are generally low, with few bursts of secretion that can be associated with 
post-prandial periods, exercise or stress 54-55. In contrast, in healthy young women, 
daytime pulses are more frequent and the sleep onset-associated surge, although 
consistently present, does not generally represent the majority of the 24-hr GH 
secretion 56-57 (Fig. 3).  
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Fig. 3: 24-hour plasma GH concentrations profiles in a healthy young male (left) and a healthy 
young female (right) 56-57 
 
 
Average 24-hour GH concentrations, as well as trough (interpulse) levels, are 
higher in women compared to men 58-60. Some authors have described an increase in 
pulse amplitude and mass secreted per burst 60-62 in women while others observed 
an increase in pulse frequency 59, 63. However, few studies have focused on gender 
differences in nighttime GH secretion; either a greater nocturnal GH production in 
men compared to age- and BMI-matched women 59, 62, or no difference in integrated 
GH concentrations 63 were reported. In the latter study women displayed a different 
secretory pattern, with a pre-sleep pulse and at least one more pulse during the 
night. The lower nocturnal GH release in women as compared to men could in fact 
be related to a higher GH secretory activity before sleep onset, reflecting a negative 
feedback inhibition of GH itself. The sexual dimorphism in the pattern of GH 
secretion is thought to be related to sex differences in GHRHergic 60, 64-66, 
somatostatinergic 59-60, 67 and/or ghrelinergic 68 tone; however, no consensus has 
been reached so far. A role for sex steroids in the feedback mechanisms controlling 
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GH secretion at the pituitary level has also been hypothesized 59, 69-70. To our 
knowledge only one study 65 looked into the mechanisms underlying sex differences 
in nocturnal GH secretion and the results suggest a lower endogenous GHRH tone 
in women.  
Fig. 4: Plasma GH profile during normal nocturnal sleep, sleep deprivation and daytime recovery 
sleep 71  
 
The sleep-onset-associated GH surge is mostly maintained and in subjects living in 
free-running conditions, i.e. without any time cues 72, as well as in subjects exposed 
to a 3-hour sleep-wake cycle for 10 days 73. Similarly, night shift workers exhibit a 
GH secretory peak in the first half of their daytime sleep period 74. These results 
were confirmed by delaying sleep by 8 or 12 hours in young, healthy, day-active 
men 74-75 (Fig. 4). 
Conversely, awakenings interrupting sleep appear to interrupt GH release. Indeed, 
two independent studies have found that the GH response to GHRH administration 
is inhibited when sleep is interrupted, either spontaneously or experimentally 76-77.  
This inhibition of GHRH-stimulated GH release by awakening could be linked to a 
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concomitant pulse in cortisol secretion, which occurs consistently during full 
nighttime awakenings, as CRH administration has been shown to inhibit the GH 
response to GHRH 76. 
More in particular, sleep-onset GH release appears consistently associated with 
SWS.  The temporal coincidence between the onset of SWS and increasing 
concentrations of GH was already noted in the late 1960s 55, 78-79.  A remarkable 
study published in 1991 showed that, when plasma GH levels are sampled at very 
frequent intervals (30 seconds), the release of GH immediately follows the 
appearance of delta waves in the EEG 80. Subsequently, a direct and robust 
correlation between the amount of GH secreted and the duration of SWS episodes 
was reported 81, as well as between pulses of GH secretion and “pulses” of SWA 82. 
The latter relationship is best evidenced when GH secretory rates are estimated by 
mathematical deconvolution of GH concentrations, as illustrated in Fig. 5.  Indeed, 
a close temporal concomitance between GH secretory pulses and peaks of SWA 














Fig. 5: temporal concomitance between GH secretory pulses and peaks of SWA in a young healthy 
subject (unpublished data). 
 
 
Pharmacological interventions that increase SWS and SWA also increase GH 
release, thus demonstrating the existence of common underlying mechanisms.  
Figure 6 illustrates the findings from two separate placebo-controlled studies which 
involved administration of a drug enhancing SWS/SWA at bedtime ( a) gamma-
hydroxybutyrate, b) ritanserin). In both studies, GH secretory pulses were 
coincident with peaks of SWA in the majority of the subjects, both in the placebo 
and in the active drug conditions 82-83.  Further, in both studies, there were 
significant correlations between the increase in SWS/SWA and the increase in GH 
release.  The findings are consistent in indicating that the drug-induced increase in 
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SWA is associated with increased GH release, even though these two drugs have 
very different mechanisms of action.  
 
Fig. 6: profiles of SWA and GH secretory rate under placebo and a) gamma-hydroxybutyrate, b) 
ritanserin (adapted from 82-83). The differences in the SWA scale between the 2 studies are due to 
different amplifier settings.  
 
 
Lastly, GH release is observed more frequently during daytime naps when they 
occur in the afternoon, a time when SWS propensity is higher, than when they 
occur in the early part of the day 84-85. 
 
Despite the strong evidence for a link between SWS regulation and nocturnal GH 
release, several authors have reported significant elevations of GH levels prior to 
sleep onset or during other stages of sleep 86-88 in men as well as in women. Such 
pre-sleep GH pulses could reflect the presence of a sleep debt 71 and/or a circadian 
effect (see below).  Dissociations between SWS and nocturnal GH release have also 
been reported. In one study, partial SWS deprivation failed to suppress or delay the 
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sleep-onset GH pulse 89. In another study, in which nocturnal GH secretion was 
correlated to EEG delta power, about 50% of the subjects displayed increased GH 
secretion before sleep onset or in absence of concomitant delta activity 88. As 
discussed below, the association between GH release and SWS appears to be 
primarily mediated by GHRH.  However, because GH secretion is also under the 
control of multiple negatve regulatory mechanisms, occasional dissociations 
between pulses of GH levels and SWS are not unexpected. 
 
Circadian influences 
Although GH secretion is consistently stimulated by sleep onset and SWS, it is also 
under the influence of circadian rhythmicity, as demonstrated by several studies in 
which the sleep-wake cycle was manipulated: a higher propensity for GH secretion 
was observed when sleep occurred in the afternoon and evening 73-74, 81, 90. 
However, careful experiments conducted in a “forced desynchrony protocol” where 
subjects lived on a 28-hr sleep-wake and light-dark cycle (9h20:18h40 dark:light) 
only revealed a minimal non-significant circadian modulation of SWA 91.  
The higher propensity for GH secretion in the late evening and early night could 
also be related to the circadian nocturnal decline in somatostatin secretion. In rats, a 
circadian rhythm of somatostatin has been observed, with higher levels during the 
dark (active) phase compared to the light (inactive) phase 92 and a similar trend was 
inferred for humans. However, peripheral somatostatin levels are difficult to 
measure in humans and may not reflect somatostatin concentrations in the 
hypophysial portal blood. The role of this peptide in the generation of GH pulses in 
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humans is suggested by experiments showing the persistence of GH pulses during 
continuous GHRH infusion  93; furthermore, repeated boluses of GHRH produced a 
greater GH response to GHRH starting from the late afternoon hours, suggesting a 
decline in somatostatin action before habitual bedtime 94. However the same group 
later reported the persistence of daytime and nighttime GH pulses during 
continuous octreotide infusion 95-96, and argued that a decline in somatostatin levels 
is not the initiating event of GH pulses. Nevertheless, these findings do not exclude 
the possibility of a declining somatostatinergic tone at the time of GH pulses, since 
the amplitude of the GH increments was lower under octreotide infusion 96.  
 
Molecular and neural mechanisms underlying the relationship between GH 
release and sleep 
Rodent and human studies have identified GHRH as the primary factor underlying 
sleep-associated GH secretion.  
In rats, hypothalamic GHRH mRNA expression exhibits a circadian rhythm with 
maximum levels at the onset of the light period (i.e. the sleep period), followed by a 
progressive decrease to reach a nadir at the beginning of the dark (i.e. active) period 
97. An opposite pattern was described for hypothalamic GHRH protein content 98. 
Injection of GHRH in rodents, either intracerebroventricularly (i.c.v.), into the 
medial preoptic area or intravenously, increases the duration of SWS 99-101. 
Consistent with these observations, administration of a GHRH receptor antagonist 
or of anti-GHRH antibodies decreases NREM sleep 102-103. Furthermore, mice and 
rats with nonfunctional GHRH receptor (lit/lit mice and dw/dw rats) have lower 
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amounts of spontaneous NREM sleep than wild types 104-105. Conversely, 
spontaneous dwarf rats, characterized by GH deficiency due to a mutation of the 
GH gene, have a longer duration of spontaneous NREM sleep, as well as a higher 
hypothalamic GHRH mRNA content compared to control rats 106, consistent with 
increased central GHRH tone due to the absence of feedback inhibition of GH. The 
majority of GHRH-producing neurons are located in the arcuate nucleus of the 
hypothalamus but another, smaller, GHRHergic neuronal population is present in 
the ventromedial nucleus and in the parvicellular portion of the paraventricular 
nucleus. These neurons have been shown to project to the anterior 
hypothalamus/preoptic area, and in particular to the ventrolateral preoptic (VLPO) 
nucleus, which is very active during SWS 57, 107. Recently, Peterfi et al. 108 evaluated 
the effect of i.c.v. GHRH, octreotide or GHRH antagonist administration, on sleep 
patterns and activation of sleep-active neurons in the hypothalamus in male rats. 
GHRH given at the beginning of the dark period, i.e. the active period, increased 
the duration of NREM sleep and SWA; immunohistochemistry staining of 
hypothalamic sections showed an increased activation of GABAergic neurons 
(Fos+GAD-positive cells) in the VLPO and in the median preoptic nucleus 
(MnPN), which is consistent with the sleep-related activity of these areas. Similar 
immunohistochemistry results were observed when the animals underwent sleep 
deprivation. Conversely, octreotide and the GHRH antagonist injected i.c.v. at the 
beginning of the light phase (i.e. the resting period), decreased the duration of 
NREM sleep and SWA, as well as the number of Fos+GAD-positive cells.  These 
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data provide functional and anatomical evidence for a role of GHRH in the 
regulation of NREM sleep.  
Results of studies performed in humans are summarized in Table 2. The first study 
in which GHRH was administered to human subjects involved an i.v. injection in 
the morning or in the evening, one hour prior to bedtime; no change in sleep 
parameters was reported 109. Another group administered a single dose of GHRH to 
healthy male volunteers at sleep onset and did not observe any change in sleep 
architecture 110. In these 2 experiments, GH levels increased in response to GHRH 
administration. Several subsequent studies in humans have shown that single 
intravenous boluses of GHRH produce an increase in both GH and SWS or SWA. 
In one study the stimulation of SWS became apparent only at a time when the 
physiological propensity for SWS was low, i.e. in the second half of the night 111. 
Other authors did observe an increase in SWS after a single bolus of GHRH, 
however the dose administered was higher than in the latter report 112. In a few 
studies, GHRH was injected in a repetitive fashion starting before sleep onset, and a 
stimulatory effect of GHRH on SWS was observed in men 112-114, but not in women 
in whom GHRH had instead sleep-impairing effects consisting in a decrease of 
stage IV sleep and of REM sleep during the first half of the night 115-116. One group 
evaluated the effect of intranasal administration of GHRH, as little is known about 
the ability of GHRH to cross the blood-brain barrier, and the intranasal route 
bypasses the blood-brain barrier; an increase in SWS duration was observed as well, 
which was significant over the second half of the night, again at a time of lower 
SWS propensity. Surprisingly, GH concentrations were decreased after GHRH, an 
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effect that the authors attribute to direct GHRH action on the CNS 117.  Contrasting 
with the evidence in support of a role of GHRH in both SWS and GH stimulation, a 
study in healthy young men showed that the blockade of endogenous GHRH 
receptors by continuous i.v. infusion of a selective GHRH antagonist had no effect 
on sleep parameters, and in particular on SWS, while it did suppress GH response 
to GHRH stimulation 118. However, it was not clear whether this GHRH antagonist 
could cross the blood-brain barrier. 
 
Table 2: Human studies about the effect of exogenous GHRH on sleep. 
Authors Protocol Results 
Garry et al., 1985109 50 μg GHRH i.v. at 9 am or 8 pm  
6 healthy young men  
No changes in GH secretion and 
sleep parameters observed 
Kupfer et al., 1991110 0.5 μg/kg GHRH i.v. at bedtime  
10 healthy young men 
Significant ↑ in GH secretion 
No change in SWS duration or 
delta activity 
No change in REM duration or 
intensity 
Steiger et al., 1992119 50 μg GHRH x4 q1h starting at 10 pm 
7 healthy young men 
Significant ↑ in GH secretion 
Significant ↑ in SWS duration 
Kerkhofs et al., 
1993111 
0.3 μg /kg GHRH iv (8 healthy young 
men) 
- at the beginning of  the 1
st
 SWS or at the 
beginning of the 3
rd
 REM cycle (sleep 
from 11 pm to 7 am) 
- at the beginning of the 1
st
 SWS after 
sleep deprivation (sleep from 4 am to 12 
pm) 
No effect if administered at the 
beginning of SWS (either after 
normal sleep or after sleep 
deprivation) 
Significant ↑ in SWS duration 
and ↓ awakenings if 
administered at the beginning of 
REM 
Marshall et al., 
1996114 
200 μg GHRH in continuous infusion or 
50 μg x4 q1h starting at 10 pm  
12 healthy young men 
Repetitive administration ↑  
SWS more than continuous 
administration (first half of 
night) 
Similar ↑ in GH secretion 
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Authors Protocol Results 
Marshall et al., 
1999112 
50 μg GHRH in i.v. bolus or  
10 μg x4 q15 min starting at 10 pm 
16 young and middle-aged healthy 
subjects 
Trend for ↑  SWS after single 
bolus 
No change in sleep parameters 
after repetitive administration  
↑ in GH secretion (more after 
single bolus) 
Perras et al., 1999117 300 μg GHRH intranasally before 
bedtime 
12 young healthy and 12 old healthy 
subjects 
↑  SWS duration in the second 
half of the night 
↓ GH secretion 
Jessup et al., 2004118 GHRH antagonist 33 μg/kg/hr 9 pm- 9am 
+ GHRH 0.33 μg/kg at 7 am i.v. 
11 healthy young men 
↓ GH secretion (spontaneous 
nocturnal and after GHRH) 
No changes in sleep parameters 
Mathias et al.,2007 
116 
  
25 or 50 μg GHRH x4 q1h starting at 10 
pm  
8 healthy premenopausal women 
↓ SWS with 50 μg GHRH x4  
↓ REM with 25 μg GHRH x4 
(first half of night) 
 
Ghrelin has been identified as a potent GH secretagogue based on the effects of 
exogenous administration. However, so far, studies attempting to evaluate the 
physiological relationship of endogenous ghrelin levels to spontaneous GH 
secretion have yielded inconsistent results 1, 120-125. A large body of evidence 
supports the notion that ghrelin acts on GH secretion at least in part via a 
stimulation of GHRH 126-129 and thus a positive interaction between central 
ghrelinergic activity and SWS/SWA should be expected. Additionally, ghrelin acts 
as a functional somatostatin antagonist at both the pituitary and the hypothalamic 
level 127, 130. Nevertheless, the interaction between ghrelin and sleep regulation is 
still poorly understood. Intracerebroventricular administration of ghrelin in rats was 
shown to increase arousal and food intake 131-133. However, systemic administration 
of ghrelin in mice had clear somnogenic effects, and ghrelin-KO mice display 
decreased NREM sleep, increased REM sleep and wakefulness 134. In humans, 
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systemic ghrelin administration at sleep onset was reported to promote SWS, as 
well as nocturnal GH secretion, in healthy young men 135.  These findings were 
reproduced in 2 later studies in young and elderly men 136-137, but not young and 
elderly women 137-138. At the moment little is known about the molecular 
mechanisms underlying the modulatory effects of ghrelin on the sleep-wake cycle; 
the effects of systemic ghrelin could be mediated by the GHRH circuitry, while 
centrally administered ghrelin could act on different hypothalamic systems 139.  
The orexin/hypocretin system is another newly identified player in the complex 
mechanisms underlying the relationship between sleep and GH secretion. 
Orexins/hypocretins, produced by neurons in the lateral hypothalamic area, were 
originally thought to be regulators of food intake 140-141. However, it emerged from 
subsequent studies that these peptides were also involved in the modulation of the 
sleep-wake cycle 142-144 as an orexin deficiency is underlying most cases of animal 
and human narcolepsy 145. Orexins also appear to be participating in the control of 
all of the endocrine axes 4. In particular, orexinergic projections have been 
identified in the arcuate nucleus and the periventricular nucleus, where neuronal 
populations express orexin receptors 144. Interconnections between ghrelinergic and 
orexinergic neurons in the hypothalamus have also been reported 146. The 
somatotrophs express both orexin-A and the orexin-receptor 1 4. In rats, i.c.v. 
orexin-A administration was found to decrease both GH secretion and pulsatility, 
an effect thought to be due to either inhibition of GHRH tone and/or increasing 
somatostatinergic tone in the hypothalamus 4, 147-148. Although early reports 
suggested that spontaneous GH secretion might be blunted in narcoleptics, these 
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were either not case-control studies, or patients and controls were not matched for 
age and BMI. A recent study by Overeem et al. 149, in which patients and controls 
were carefully matched for age, gender, BMI and body fat, found  that narcoleptic 
patients with CSF orexin deficiency are not GH deficient. Furthermore, the patients 
maintained a temporal relationship between GH release and SWS episodes, 
although the proportion of GH secreted during daytime was increased, as compared 
to controls.  This altered circadian distribution of GH secretory events could be due 
to the lack of modulatory effect normally exerted by the orexin system on GHRH 
secretion during the daytime.  
 
Exogenous GH and sleep 
The impact of GH administration on sleep was evaluated in several animal studies: 
in mice, rats and cats, exogenous GH increases REM sleep duration 150-151. 
In the first study performed in humans 152, human GH obtained from pituitary 
extracts was administered intramuscularly (i.m.) to healthy volunteers 15 minutes 
before bedtime. Compared to saline, 2 UI of hGH i.m. did not alter sleep 
parameters, while at higher doses (5 UI) a significant increase in REM duration and 
a significant reduction in SWS duration were observed. The same authors failed to 
reproduce these results in a later study, in which, however, hGH (2UI i.m.) was 
administered twice daily (8 am and 5 pm) for 3 days before sleep was recorded; the 
lack of impact of GH on sleep might be related to the time lapse between the last 
administration and bedtime 153. Kern et al. 154 administered rhGH (either 5 UI i.m. 
before bedtime or in continous i.v. infusion overnight, or 48 UI i.v. over 30 minutes 
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at bedtime) to healthy male volunteers: no changes in sleep parameters were 
observed. 
 
Sleep in GHD patients  
Very few studies have objectively characterized sleep in GHD patients and the 
results, summarized in Table 3, have been inconclusive. The first ones were carried 
out in children: Orr et al. evaluated 10 children with isolated GHD, who displayed 
similar sleep parameters as their age-matched controls, except for REM sleep that 
was significantly shorter in the younger age group 155. Wu and Thorpy observed an 
increase in stage 1 and SWS in children with isolated GHD compared to an age-
matched control cohort taken from literature 156. One later study involved young 
adults with childhood-onset isolated GHD and a decrease in SWA was reported in 
the patients 157. Finally, a study on women with Sheehan’s syndrome showed an 
increase in SWS duration in the patients compared to controls matched for age, 
BMI and menopausal status 158. 
Sleep characteristics in GH deficient patients have also been studied during GH 
replacement therapy. Wu and Thorpy observed a decreased duration of stage 3 in 
children with isolated GHD treated for 1 to 2 weeks 156. In adults, SWS duration 
was reported to be shorter after 6 months on rhGH in young adult patients with 
isolated GHD 159, increased in middle-aged patients with GHD of variable origin 





Table 3: studies evaluating sleep in GHD patients published in literature (CO childhood-onset, 
aGHD adult GHD, iGHD isolated GHD, PSG polysomnography). 
Authors Protocol Results 
Orr et al., 1977 155 10 children with iGHD vs controls 
PSG study 
No difference in SWS duration 
Wu and Thorpy, 1988 
156 
7 children with GHD 
PSG study before and after 1-2 
weeks of hGH treatment 
GH treatment: ↓ stage III duration 
Comparison with a cohort of normal 
age-matched children: ↑ stage I, III, 
IV in GHD patients  
Astrom et al., 1989157 7 young adults with CO-iGHD vs 
controls 
PSG study + power spectral 
analysis 
↓ delta power in GHD patients 
Astrom et al., 1990159 8 young adults with CO-iGHD 
PSG study before and after 6 
months hGH treatment 
↓ total sleep time 
↑ REM sleep  
No change in SWS duration 
Nolte et al., 2002 160 5 patients with aGHD due to 
pituitary disease 
PSG study after 1 yr of rhGH 
treatment and after 6 months 
withdrawal 
On rhGH: normal duration of stage I, 
II and SWS, ↓ sleep efficiency, ↓ 
REM 
After rhGH withdrawal: ↓ SWS 
Schneider et al., 2005161 18 aGHD patients 
PSG study after 6 months rhGH 
treatment vs placebo 
No difference in sleep parameters 
Peker et al., 2006 162 19 aGHD patients 
PSG study before and after 6 
months rhGH treatment 
No difference in sleep parameters 
(↑ REM in patients with OSA) 
Ismailogullari et al., 
2009 158 
22 women with Sheehan’s 
syndrome  
vs controls and after 6 months 
rhGH 
Vs controls: ↑ Stage IV, ↓ REM, ↓ 
sleep efficiency 




AIM OF THE STUDY  
Not a single study has assessed subjective sleep quality or daytime sleepiness in 
GHD as compared with normal controls. Furthermore, the studies looking at the 
impact of rhGH administration on sleep architecture and quality have yielded 
inconclusive results.  The purpose of our study was therefore to: 
1. characterize objective sleep quality, as well as subjective sleep quality, daytime 
sleepiness and QoL in a large cohort of untreated adult patients with GHD, 
individually matched for gender, age and body mass index (BMI) with control 
subjects.  
2. assess the impact on sleep and subjective sleepiness of a 4-month period of rhGH 
treatment in aGHD patients, as compared to placebo, in a single-blind placebo-
controlled design.  
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SUBJECTS AND METHODS  
   
Patients  
Thirty adults with GHD (26 males, 6 females), aged 45±18 years (19-74) and with a 
BMI of 27.4±1 kg/m2 were enrolled in the study. These patients were recruited in 
four centers: 
a. Sleep, Chronobiology and Neuroendocrinology Research Laboratory, Department of 
Medicine University of Chicago, USA;  
b. Department of Endocrinology and Centre d’Etude des Rythmes Biologiques, 
Université Libre de Bruxelles, Belgium; 
c. Department of Endocrinology, Université de Liège, Belgium;  
d. Department of Endocrinology, Università di Pisa, Italy.  
 
Diagnosis of GHD 
The diagnosis of GHD was based on an intravenous insulin tolerance test or a 
GHRH+arginine test performed within the last 5 years, with a maximum GH 
response <3 ng/ml for ITT or according to BMI for GHRH+arginine (BMI <25 
kg/m2, peak GH <11 mg/l; 25≤BMI<30 kg/m2, peak GH<8 mg/l; BMI ≥30 kg/m2, 




Screening included a clinical examination and routine laboratory measurements. 
Patients with evidence of substance abuse, liver disease, renal insufficiency, heart 
failure, malignant disease, chronic infectious disease, neurological or psychiatric 
disease, clinically significant hyperprolactinemia, or diabetes requiring 
administration of insulin or sulfonylurea, were excluded from the study. Individuals 
employed as shift workers within the last 3 months and subjects having traveled 
across more than 2 time zones within the last 2 weeks were not included. All 
subjects were off hypnotic drugs for at least 3 months.  
 
Patients characteristics 
Six patients had childhood onset idiopathic GHD, while the remaining 24 patients 
had an adult onset GHD. The patients had either never received GH therapy or were 
off GH treatment for at least 6 months at the time of enrollment.  
The individual diagnoses and additional pituitary hormone deficiencies, as well as 
treatment, are presented in Table 4. 
In 12 of the 30 patients, the origin of the adult onset GHD was a primary pituitary 
defect without supra-pituitary involvement: surgical removal of a pituitary tumor 
without radiotherapy (10 patients); spontaneous necrosis of a pituitary tumor (1 
patient); pituitary stalk section (1 patient). None of these patients presented with 
diabetes insipidus.  
In 6 additional patients, the existence of primary pituitary lesions was confirmed but 
a supra-pituitary involvement could not be excluded: surgical removal of a pituitary 
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tumor with diabetes insipidus (2 patients); radiotherapy for a pituitary tumor (1 
patient); surgical removal of a craniopharyngioma, without any adherence to the 
hypothalamus or the optic chiasm, with presence of diabetes insipidus (2 patients); 
spontaneous necrosis of a pituitary tumor with diabetes insipidus (1 patient). Both 
pituitary and hypothalamic lesions were possible in two other patients (1 
neurosarcoidosis, 1 histiocytosis).  
Consistent with known genetic causes for “idiopathic” pituitary deficiencies 163, a 
primary pituitary origin of GHD was considered very likely in the 6 patients with 
childhood-onset idiopathic GHD. A primary pituitary defect was excluded in the 
remainder 4 patients (referred to as “hypothalamic”): 1 brain tumor (surgery and 
radiotherapy, diabetes insipidus), 1 cerebral trunk thrombosis, 1 olfactory duct 
tumor (surgery), 1 pineal gland tumor (radiotherapy, diabetes insipidus).  Based on 
these considerations, patients were divided into 3 categories according to the origin 
of the GH deficit:  
- pure pituitary (n=18),  
- pituitary with likely hypothalamic involvement (n=8),  
- hypothalamic (n=4). 
Twenty-eight of the 30 patients had associated pituitary hormonal deficiencies and 
were on appropriate and stable replacement therapy, as assessed by at least two 
clinical and biological evaluations performed at intervals of at least 3 months. All 6 
female patients were on estrogen (4 also on progesterone/progestagen) replacement 
therapy; 16 male patients with gonadal insufficiency were treated with testosterone 
(intramuscular injections of 200-250 mg every 2-3 weeks or transdermal 
 33
applications of 50 mg/day); 21 patients with thyroid insufficiency received oral L-
thyroxine (50-250 μg/day); 24 patients with adrenal insufficiency received oral 
hydrocortisone (20-30 mg/day), or cortisone acetate (25-37.5 mg/day), averaging 
12.0±0.7 mg/m2/day hydrocortisone or the  
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Table 4: Clinical characteristics of the patients (NFPA non functioning pituitary adenoma, surg 
surgery, RT radiotherapy, AO adult-onset, CO childhood-onset, CDI  central diabetes insipidus) 
 






C D I 
Bxl01 M 64 25 NFPA + surg AO X    
Bxl02 M 60 23.2 NFPA + surg AO X    
Bxl03 M 28 17.8 Idiopathic CO   X  
Bxl04 F 70 24.1 Prolactinoma + surg AO X X X  
Bxl05 M 69 30.1 NFPA + surg AO X X X  
Bxl06 F 74 32.9 Cerebral thrombosis AO  X X  
Bxl07 M 29 26 Pituitary stalk 
section 
AO X X X  
Bxl08 M 22 21.4 Idiopathic CO X X X  
Bxl09 M 47 32.7 Idiopathic CO X X X  
Bxl10 M 36 44 Neurosarcoidosis 
with hypothalamic 
infiltration 
AO X X X X 
Bxl11 M 47 26.7 Idiopathic CO X X X  
Bxl12 M 30 29.5 Craniopharyingioma 
+ surg 
AO X X X X 
Bxl13 F 65 27.9 Cushing’s disease + 
surg 
AO X  X  
Bxl14 M 29 20.7 Idiopathic CO X X X  
Bxl15 M 49 29.4 Olfactory duct 
meningioma 
AO     
Bxl16 M 54 28.7 NFPA + surg AO X X X  
Bxl17 M 33 22.5 Pinealoma + RT AO    X 
Bxl18 M 74 27.7 NFPA + surg AO X X   
Chi01 M 27 24 Craniopharyngioma 
+ surg 
CO X X X X 
Chi02 M 51 28.4 Histiocytosis + RT AO X X X  
Chi03 M 58 23.7 NFPA + pituitary 
apoplexy 
AO X X X  
Chi04 M 54 34.4 NFPA + pituitary 
apoplexy 
AO X X X X 
Chi05 F 21 29 Brain tumor + RT + 
chemotherapy 
AO X X X X 
Chi06 M 41 30 Prolactinoma + RT AO X X X  
Chi07 M 71 28.2 NFPA + surg AO X X X  
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C D I 
Chi08 F 21 25.1 NFPA + surg AO X X X X 
Chi09 M 19 21.9 NFPA + surg AO X   
Chi10 M 24 36.2 Idiopathic CO    
Chi11 F 32 21.9 NFPA + surg AO   X X 
Chi12 M 43 25.3 NFPA + surg  AO X X  
 
equipotent dose of cortisone; 7 patients with diabetes insipidus were treated with 
desmopressin.  
   
Controls  
Thirty healthy controls were individually matched with the patients for gender, age 
and BMI. Women were also matched for formulations of estrogens and 
progesterone/progestagens. Whenever applicable, inclusion criteria were the same 
as for the patients.  
   
Experimental protocol  
The protocol was approved by the Institutional Review Boards of all participating 
universities. Written informed consent was obtained from all participants.  
The protocol is illustrated in Fig. 7 and consisted of: 
 a first 4-month phase during which either rhGH or placebo were administered to 
the GHD patients; objective and subjective sleep quality, as well as quality of life, 
were evaluated at baseline in patients and controls (study A) and at the end of the 4 
months in patients (study B1) 
 a 3-month wash-out period 
 a second 4-month phase during which either placebo or rhGH were administered 
to the GHD patients; objective and subjective sleep quality, as well as quality of 





 Fig. 7: outline of the procotocol (PSQI Pittsburgh Sleep Quality index, QoL-AGHDA Quality of 




The outpatient visit and the inpatient study were performed in laboratories at the 
Universities of Chicago, Brussels (including the patients recruited at the University 
of Liege) and Pisa. The same equipment, instruments and recording techniques 
were used at each site.  
Outpatient visit  
All GHD patients and control subjects had an initial outpatient admission. This visit 
included: 
- physical examination; 
- administration of the QoL scale (QoL-AGHDA): 25 “yes or no” questions relative 
to specific complaints commonly reported by GHD patients. A higher score 
corresponds to lower QoL. The 25 complaints may be clustered in five domains: 
tiredness (7 questions), memory and concentration (6 questions), tenseness (3 
questions), social isolation (5 questions), and self-confidence (4 questions) 30, 37. For 
each domain, the mean score per question was calculated.  
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- administration of the Pittsburgh Sleep Quality Index questionnaire (PSQI): a 
validated 19-item questionnaire that investigates subjective sleep quality, as well as 
subjective sleep latency, subjective sleep duration, subjective sleep efficiency, 
presence of sleep disturbances, use of hypnotic drugs and daytime sleepiness; 
scores can range from 0 and 21 and a score > 5 is indicative of impaired sleep 164. 




Patients and controls underwent 6 days of ambulatory sleep monitoring by wrist 
actigraphy (Actiwatch, Philips Respironics, Bend, OR), a method providing 
accurate estimations of sleep onset and offset 165-166. The median habitual bedtimes 
from these recordings were used to individually design the bedtime schedule during 
the inpatient study. Patients and controls also had to fill a questionnaire about the 
subjective quality of their sleep every morning (Karolinska Sleep Log) and keep a 
log of their caffeine and alcohol intake for those 6 days. 
Inpatient study 
Fig. 8: outline of the inpatient study (N1 night 1, N2 night 2) 
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The outline of the inpatient study is shown in Fig. 8. Within one week after the end 
of ambulatory monitoring, the subjects were admitted to the laboratory between 
1700 h and 1900 h on day 1, and remained in the laboratory until discharge in the 
morning of day 3. Regular hospital meals were served at 08h00, 12h30 and 19h0. 
Lights were turned off 5 min before scheduled bedtime and turned on 5 min after 
scheduled wake time. During bedtimes, sleep was polygraphically recorded 
(DigiTrace Care Services, Boston, MA).  
Upon awakening on day 2, a blood sample was taken for measurement of plasma 
IGF-I. Thereafter, subjects were maintained under normal indoor light (± 300 lux) 
until bedtime. During waking hours, they had sedentary activities (reading, 
watching TV and simple neurobehavioral tests) and were free to ambulate around 
the unit. Naps were not allowed.  
During the second night, all experimental conditions were identical to those in the 
first night.  
Monitoring of rhGH treatment in patients 
Recombinant human GH (Genotropin, Pfizer, Inc, New York, USA) was 
administered as follows: 
Table 5: rhGH dosage instructions according to age and gender. 
 Men <45 y.o. Men >45 y.o. Women <45 y.o. Women > 45 y.o. 
Initial dose (mg/day) 0.2 0.1 0.3 0.3 
Increments (mg/day) 0.2 0.1 0.2 0.1 
Max. dose (mg/day) 0.6 0.4 0.7 0.6 
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Patients were instructed to inject rhGH subcutaneously approximately 30 minutes 
before bedtime. IGF-I levels were monitored monthly and rhGH dosage was titrated 
accordingly.  
 
Objective sleep analysis  
Polygraphic recordings were visually scored at 30-sec intervals in stages wake, I, II, 
III, IV and REM using standardized criteria 41 by the same experienced scorer who 
was blind to the subject’s condition. Sleep onset and morning awakening were 
defined as, respectively, the times of the first and last 30-sec intervals scored II, III, 
IV, or REM. The sleep period was defined as the time separating sleep onset from 
final morning awakening. Total sleep time was defined as the sleep period minus 
the total duration of wake after sleep onset (WASO). Sleep latency was defined as 
the time from lights off until sleep onset (Fig. 9). Sleep efficiency was calculated as 
the total sleep time, expressed as percentage of the time allocated to sleep. A 
spectral analysis on the central EEG lead was performed (PRANA, PhiTools, 
Strasbourg, France) 167. Muscular, ocular and movement artifacts were eliminated 
prior to spectral analysis. Delta, theta, and alpha activities were calculated as the 
absolute spectral power in the frequency bands 0.5-4 Hz, 4.5-8 Hz, and 8.5-12 Hz, 
respectively. Mean power per 30-sec epoch was calculated for each band. Mean 
delta power in non-REM sleep quantifies the intensity of SWS. For illustrative 
purposes, the durations of NREM/REM cycles were also normalized to account for 
individual differences 168. 
 
 41
Fig.9: sleep parameters recorded during each night. 
 
For study A, technical artifacts prevented sleep scoring for 3 of the 120 nights of 
recordings and spectral analysis for 9 of the 120 nights. All of the 52 nights 
recorded for study B were scored; technical artifacts prevented spectral analysis for 
5 of them. With very few exceptions due to technical failures, comparisons between 
patients and controls used the second, rather than the first night of 
polysomnography, because all patients and controls were habituated to the 
experimental procedures and spent the preceding day in the same standardized and 
controlled environment.  
 
Statistical analysis  
For study A, the analysis principally compares the 26 GHD patients with confirmed 
or likely pituitary defects, and their individually matched controls. Because sleep 
quality changes in the course of normal aging42, we performed a median split of this 
group according to age (younger: 29±2 years, range 19-43 years, n=13; older: 60±3 
years, range: 47–74 years, n=13) and compared patients and controls by ANOVA 
for repeated measures with age group as a between-subject factor. Differences in 
the prevalence of QoL symptoms were tested by the Chi-Square test with Yates’ 
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correction for continuity. Correlations were explored using the Spearman 
coefficient.  
We also compared the 12 patients with pure primary pituitary GHD, the 8 patients 
classified as pituitary GHD with possible hypothalamic involvement, the 6 patients 
with childhood onset idiopathic GHD and the 4 hypothalamic GHD patients. 
Differences between patients and their individually matched controls were 
compared by ANOVA with etiology of GHD as factor and age group as covariate.  
For study B, differences between the 2 treatment periods were compared by 
ANOVA for repeated measures with treatment as a factor and age group as 
covariate.  




Clinical characteristics for each GHD group and for matched controls are shown in 
Table 6. IGF-I values were lower in all GHD patients than in individually matched 
controls, averaging 72±7 ng/ml vs 194±11 ng/ml (p<0.001). GHD patients had 
normal plasma levels of fasting glucose, sodium and potassium. Plasma fT4 levels 
averaged 86±5 % of the median value of the normal range.  
Table 6: Demographics of GHD patients and their age, gender and BMI-matched controls. 
GHD patients Controls 
Associated deficits (% patients) Groups M/F Age 
(yr) 
BMI 












7/1 39±5 31±2 100 100 100 63 39±5 31±2 
Idiopathic (6) 6/0 33±5 26±3 67 67 67 0 33±5 25±3 
Hypothalamic 
(4) 
2/2 44±11 28±2 50 25 50 25 45±11 26±2 
 
We first present detailed analyses for the 26 patients with pure pituitary defects, 
pituitary defects with possible hypothalamic involvement, or likely pituitary 
defects. An exploratory analysis of differences with patients with hypothalamic 
GHD follows.  
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Objective sleep quality  
Table 7 presents the sleep parameters recorded in the 26 patients with pure pituitary 
defects, pituitary defects with possible hypothalamic involvement, and idiopathic 
GHD, and their gender, age and BMI-matched controls. 
Table 7: Sleep variables recorded in 26 patients with pure pituitary defects, pituitary defects with 
possible hypothalamic involvement, and childhood-onset idiopathic GHD, and their individually 





GHD vs controls 
p level 
Age 
young vs older 
p level 
Age x condition 
interaction 
p level 
SPT (min) 488±12 482±11 0.75 0.77 0.83 
Sleep latency (min) 32±7 27±4 0.46 0.59 0.94 
TST (min) 432±11 477±9 0.14 0.004 0.01 
Sleep efficiency 
(%) 
83±2 88±1 0.05 0.001 0.03 
WASO (min) 51±11 28±5 0.05 0.002 0.04 
REM sleep (min) 91±7 100±5 0.28 0.002 0.05 
Stages I+II (min) 220±11 267±14 0.02 0.93 0.70 
Stage III (min) 47±5 37±4 0.06 0.67 0.17 
Stage IV (min) 68±7 44±6 0.01 0.02 0.58 
 
Bedtimes, sleep period and sleep latencies were similar in GHD patients with 
primary pituitary lesions and controls, irrespective of age. While total duration of 
NREM sleep was not modified, GHD patients presented a shift of NREM sleep 
towards deeper stages, with lower amounts of stages I+II, and a more than 50% 
increase in the duration of stage IV. Differences between GHD patients and controls 
for total sleep time, sleep efficiency, WASO and REM were dependent on age (as 
revealed by a significant interaction between age and condition). Figure 10 
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illustrates the differences between GHD patients and controls for the sleep variables 
and the two age groups. The elevation in SWS (stages III+IV) relative to controls 
was significant in the entire group of GHD patients and in the younger group, but 
failed to reach statistical significance in the older group. Total sleep time was 
decreased and sleep fragmentation (as quantified by sleep efficiency and WASO) 
was increased in older, but not in younger GHD patients, as compared to controls. 
The increase in WASO in older subjects was not significant during the first 3 hours 
of sleep (GHD patients: 23±7 min; controls: 16±6 min; p=0.39) and reflected 
mainly sleep fragmentation during the later part of the night (hours 3-6 of sleep: 
39±9 min vs 13±2 min, p=0.009). The reduction in total sleep time in older GHD 
patients was associated with lower amounts of REM sleep.  
 
Fig. 10: Differences (mean±SEM) in total sleep time, sleep stages and delta activity between 26 
GHD patients with pure pituitary defects, pituitary defects with possible hypothalamic involvement, 
or childhood onset idiopathic GHD, and their pair-matched healthy controls for the younger (n=13) 
and the older (n= 13) age groups. Positive values indicate higher levels in GHD patients, negative 




Mean profiles of delta, theta and alpha activities in both groups of 26 subjects are 
shown in Fig. 11. The normal homeostatic decline of delta activity occurred across 
the night in both groups. However, delta and theta activities were markedly higher 
in GHD patients than in controls.  
 
 
Fig. 11: Mean profiles (+SEM) of absolute EEG spectral power in the delta, theta and alpha ranges 
during the first four NREM-REM cycles in GHD patients with pure pituitary defects, pituitary 
defects with possible hypothalamic involvement, or childhood-onset idiopathic GHD (left), and in 
their healthy controls (right).  
 
Throughout the first 6 hours after sleep onset, mean delta activity in NREM sleep 
was increased by more than 50% in GHD patients as compared to controls. Theta 
power was also increased in patients compared to controls (Table 8). The elevation 
in delta power relative to controls was significant in the entire group of GHD 
patients and in the younger group, but failed to reach statistical significance in the 
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older group. EEG spectral power in the alpha range was not affected by GH 
deficiency. 
 
Table 8: Mean spectral power levels in the delta, theta and alpha power, in GHD patients with pure 
pituitary defects, pituitary defects with possible hypothalamic involvement, or childhood-onset 










Age x condition 
interaction 
p level 
Mean delta power 
(µV2) 
1284±227 837±99 0.03 0.01 0.23 
Mean theta power 
(µV2) 
146±27 96±12 0.05 0.47 0.94 
Mean alpha power 
(µV2) 
58±9 51±6 0.53 0.95 0.27 
 
Subjective sleep quality and daytime sleepiness 
On average, the global PSQI was indicative of poor sleep (i.e. above the clinical 
cut-off of 5) in the 26 GHD patients with primary pituitary lesions while it was 
consistent with normal sleep in their controls (6.6±0.7 vs 3.6±0.5, p=0.04). The 
component assessing daytime sleepiness was also elevated in these patients as 
compared to their controls (1.1±0.2 vs 0.5±0.1, p=0.03 by paired Wilcoxon test).  
No significant correlations were found between the global PSQI score and 
polysomnography-derived sleep variables. However, the daytime sleepiness 
component of the PSQI was associated with reduced sleep efficiency (rs=-0.55, 
p=0.006) and longer WASO (rs=0.47, p=0.02).  
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Quality of Life  
Group data for QoL variables for the 26 patients with primary pituitary lesions and 
their matched controls are given in Table 8.  
QoL scores were similar in U.S. and European patients. GHD patients had 
significantly higher total QoL-AGHDA scores than their controls, irrespective of 
age, but the scores were not indicative of a major impairment. Tiredness was the 
most frequent complaint and reached the highest score in both age groups. Only 
30% of patients (8/26), as compared to 73% of controls (19/26), did not report any 
tiredness complaint (negative answer to each of the 7 questions; p<0.01). Memory 
problems were also more frequent in GHD patients than in controls.  
 
Table 9: Global quality of life scores and scores for the different domains explored by the QoL-
AGHDA questionnaire, in GHD patients with pure pituitary defects, pituitary defects with possible 
hypothalamic involvement, or childhood onset idiopathic GHD, and in their healthy controls. For 
each domain, the mean score per question was calculated. 





young vs older 
p level 
Age x condition 
interaction 
p level 
Global score 6.85±1.24 2.85±0.85 0.006 0.93 0.49 
Tiredness 0.31±0.06 0.07±0.03 0.001 0.94 0.93 
Memory and 
concentration 
0.30±0.07 0.15±0.05 0.0 0.81 0.11 
Tenseness  0.39±0.07 0.22±0.07 0.08 0.29 0.48 
Social isolation 0.20±0.06 0.08±0.03 0.07 0.51 0.48 
Self-confidence 0.18±0.05 0.11±0.05 0.26 0.43 0.57 
 
Figure 12 illustrates the differences between GHD patients and controls for the five 
domains of QoL and the two age groups. When each age group was analyzed 
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separately, tiredness was the only domain significantly affected in young patients, 
while deficits in memory and concentration, and a trend for more social problems 
were also found in older patients.  
Fig. 12: Differences (mean+SEM) in quality of life scores for the five domains of the QoL-AGHDA 
scale between GHD patients with pure pituitary defects, pituitary defects with possible hypothalamic 
involvement, or childhood onset idiopathic GHD, and their pair-matched healthy controls for the 




In the entire group of 26 patients, the score on the tiredness domain of QoL was 
associated with the daytime sleepiness component of the PSQI (rs=0.41, p=0.04). In 
younger patients (n=13), a trend for a correlation between the tiredness score and 
the amount of SWS was detectable (rs=0.51, p<0.08) (Fig. 13). No other 
correlations between sleep variables and global or partial QoL scores were found.  
Fig.13: correlation between QoL-AGHDA tiredness score and SWS duration in younger patients 
(n=13) with aGHD. 
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Impact of etiology of GHD on objective sleep variables, subjective sleep 
quality and quality of life  
Irrespective of GHD etiology (i.e. pure pituitary, pituitary with possible 
hypothalamic involvement, idiopathic childhood onset, hypothalamic), differences 
between patients and controls were qualitatively similar for all sleep variables 
derived from sleep staging as well as for subjective sleep quality and QoL. 
However, EEG spectral analysis revealed striking differences in the 
microarchitecture of non-REM sleep in patients with hypothalamic GHD as 
compared to those with pituitary GHD.  
Fig. 14: Mean (+SEM) of absolute EEG spectral power in the delta range during the first four 
NREM-REM cycles in GHD patients as compared to their matched controls for the four diagnostic 
categories. From top to bottom: pure pituitary GHD (n=12), pituitary GHD with possible 
hypothalamic involvement (n=7), childhood onset idiopathic GHD (n=6), hypothalamic GHD 
patients (n=4). Differences in levels of delta activity across the four control groups are due to 
differences in sex, age and BMI distribution. For each diagnostic category, patients and controls are 
pair-matched for sex, age and BMI.  
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Indeed, as illustrated in Figure 15, the etiology of GHD was a significant predictor 
of the difference in delta activity between patients and controls after adjusting for 
age (p=0.05). In patients with hypothalamic GHD, the findings regarding delta 
activity were opposite from those observed in patients with “pure pituitary” GHD 
(p=0.005) or patients with childhood onset idiopathic GHD (p=0.05), with 
markedly decreased, rather than increased, delta activity in patients as compared to 
controls.  
Fig: 15: Differences (mean±SEM) between patients and controls in total delta activity during the 
first 6 hours of sleep for: patients with pure pituitary GHD (n=12); patients with pituitary GHD with 
possible hypothalamic involvement (n=7; spectral analysis could not be performed for one patient); 
patients with childhood-onset idiopathic GHD (n=6); patients with hypothalamic GHD (n=4). 
Positive values indicate higher levels in GHD patients, negative values lower levels in GHD patients. 
** p<0.005 for difference between pure pituitary GHD and hypothalamic GHD, after controlling for 







13 patients completed phase B of the study (11M, 2F, age 465 years). Six patients 
were part of the “young” category and 7 were part of the “older” group. The 
average dose of rhGH was 0.40.1 mg/day. At the end of the rhGH period, average 
IGF-I was 22730 ng/ml, vs 9415 ng/ml at the end of the placebo period 
(p=0.001). Five patients started with the placebo phase, and 8 started with the rhGH 
phase. No side-effects were reported during rhGH replacement. 
 
Impact of rhGH treatment on anthropometric measures 
As shown in Table 10, no difference was observed in BMI at the end of the 4-
months rhGH period, after controlling for the age group, compared to values 
obtained at the end of the placebo period. For the waist-to-hip ratio, data is 
available in both sessions for 9 patients. A trend for improvement was evident in 
this measure (p=0.10). Differences in body composition measures did not reach 
statistical significance, probably because data is available only for 6 patients; 
however the lean mass, and therefore the lean/fat ratio, increased with treatment. 
Table 10: Anthropometric and body composition measures obtained for GHD patients after 4 
months placebo or rhGH treatment (meanSEM).  
 
 Placebo GH Treatment 
GH vs PL 
p level 
Age group 
young vs older 
p level 





25.81.8 261.6 0.52 0.28 0.74 
WHR 
n=9 
0.920.02 0.900.02 0.10 0.45 0.13 
Fat mass (kg) 
n=6 
32.78.4 32.28.4 0.98 0.61 0.41 
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 Placebo GH Treatment 
GH vs PL 
p level 
Age group 
young vs older 
p level 
Treatment x age group 
interaction 
p level 
Fat mass (%) 
n=6 




51.76.3 54.85.8 0.54 0.63 0.89 
Lean mass (%) 
n=6 




39.14.7 41.14.2 0.54 0.79 0.60 
Total body 
water (%) n=6 
47.83 503.9 0.87 0.18 0.78 
Lean/fat ratio 
n=6 
1.80.3 2.50.7 0.86 0.45 0.75 
 
Objective sleep quality 
Result of the patient with GHD of hypothalamic origin 
We present the results of this patient (a 74-year old woman who suffered a cerebral 
trunk thrombosis) separately since she is the only one in this category. 
Table 11: Sleep parameters, delta activity levels, PSQI score and AGHDA score of the patient with 
GHD of hypothalamic origin after 4 months placebo or rhGH treatment.  
 Placebo GH 
TST (min) 390.5 382 
Stages I+II (min) 314 194.5 
Stage III +IV (min) 2 79 
Stage REM (min) 74.5 108.5 
WASO (min) 163.5 63 
Delta activity in NREM  
(sum first 3 hours of sleep) 
4391 95520 
Theta activity in NREM  
(sum first 3 hours of sleep) 
11486 20862 
Alpha activity in NREM 
(sum first 3 hours of sleep) 
7234 15328 
PSQI global score 12 9 
PSQI daytime sleepiness 2 3 
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 Placebo GH 
AGHDA global score 8 n.a. 
AGHDA tiredness 0.71 n.a. 
 
Results of the other GHD patients 
Of the 12 remaining patients, 5 had a “pure pituitary” origin of the GHD, 4 patients 
had an idiopathic GHD, 3 patients had a GHD of pituitary origin with likely 
hypothalamic involvement. While reviewing the results of the spectral analysis, we 
noticed that one patient (Bxl07), a 29-year old man with a diagnosis of transsection 
of the pituitary stalk, displayed results under placebo that were inconsistent with 
those obtained during study A, i.e. also in the absence of active treatment: the delta 
activity levels in study A were approximately 7 times higher than in the placebo 
session of study B. However delta activity is highly reproducible in a single 
individual 51-52, 169 even in recordings performed at several months distance. Indeed, 
the reproducibility of delta activity in each individual was confirmed by a highly 
significant correlation between the results of study A and those of the placebo 
session of study B when this patient was excluded (rs=0.9, p=0.002; Fig. 16), while 
the correlation failed to reach statistical significance when this patient was included. 
Furthermore, the Grubbs test for detection of statistical outliers performed on the 
difference of both delta power and theta power during NREM between session A 
and PL identified this patient as a significant outlier (p<0.05). The most likely 
explanation for the difference in results observed in this patient is a technical 
artifact due to different amplifier settings. We are therefore presenting the results of 
the objective sleep analysis and of the spectral analysis for the other 11 patients.  
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 Fig. 16: Correlation between delta power in NREM in sessions A and B-placebo (B-PL) including 
(left) and excluding (right) patient Bxl07. 
 
 
The main sleep variables are presented in table 12.  
 
Table 12: Mean (±SEM) values of sleep variables in 11 GHD patients after 4 months placebo or 
rhGH treatment.  
 Placebo GH Treatment
GH vs PL 
p level 
Age group 
young vs older 
p level 
Interaction 
treatment x age 
group 
p level 
Sleep period time (min) 484±11 427±22 0.02 0.92 0.34 
Sleep latency (min) 16±5 22±10 0.28 0.21 0.60 
Total sleep time (min) 435±14 385±24 0.05 0.36 0.24 
Sleep efficiency (%) 86±3 84±4 0.33 0.24 0.38 
WASO (min) 49±3 42±11 0.56 0.07 0.79 
REM sleep (min) 82±10 67±9 0.22 0.03 0.36 
REM sleep (%) 19±2 17±2 0.51 0.14 0.42 
Stages I+II (min) 272±15 249±19 0.16 0.62 0.50 
Stages I+II (%) 64±5 66±5 0.18 0.33 0.07 
Stage III (min) 30±8 30±11 0.47 0.93 0.02 
Stage III (%) 6±2 8±2 0.64 0.99 0.02 
Stage IV (min) 52±15 39±13 0.14 0.33 0.35 
Stage IV (%) 12±3 9±3 0.09 0.24 0.38 
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Total sleep time was decreased by 50 min after rhGH treatment (385±24 vs 435±14 
min), and the difference was significant after controlling for age (p=0.05). As 
illustrated in Fig. 17, in younger subjects, this difference was mostly due to a 
decreased duration of SWS (7518 vs 11424 min). A trend for significance was 
observed when SWS was expressed as percentage of total sleep time (18.03.5 vs 
24.25.2%, p=0.07). REM sleep duration was also shorter but the difference did not 
reach statistical significance. In older patients, the decrease in sleep time was due to 
a shorter duration of the shallower stages of NREM sleep (stages I+II: 25229 vs 
27823 min, p=0.04), while SWS duration was unchanged. An impact of age was 
also observed for sleep efficiency, wake after sleep onset (WASO) and REM sleep, 
as expected.  
 
Fig. 17: Differences (mean±SEM) in total sleep time and sleep stages between placebo and rhGH for 
the younger (n=4) and the older (n=7) GHD patients. Positive values indicate higher levels under 









The average profiles of EEG delta, theta and alpha power in the 2 conditions are 
presented in Fig. 18.  
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Fig. 18: Mean profiles (+SEM) of absolute EEG spectral power in the delta, theta and alpha ranges 
during the first four NREM-REM cycles in GHD patients under rhGH (left) and placebo (right).  
 
 
During the first 3 hours after sleep onset, delta activity was decreased by rhGH 
treatment; after controlling for age group, the difference did not reach statistical 
significance (p=0.1), however, when age was taken into account as a continuous 
variable, the difference became significant (210166±62769 vs 283536±93402 µV2, 
p=0.05), and this effect tended to persist when the first 6 hours of sleep were 
considered (p=0.07). As illustrated in Fig. 19, young and older patients behaved 
differently for this measure as well, as the decrease in delta activity was much more 







Fig. 19: Mean difference (±SEM) in average EEG delta spectral power between GH and placebo 
over the first 3 and 6 hours of sleep in younger (n=4) and older (n=7) GHD patients. Negative values 




Theta activity decreased as well under rhGH, however the difference failed to reach 
statistical significance.  
 
Subjective sleep quality and daytime sleepiness 
PSQI scores are available in both sessions for 6 patients. PSQI global score was 
decreased after treatment with rhGH (4.50.7) compared to placebo (61.3), 
however the difference failed to reach statistical significance (p=0.23). 
Nevertheless, these results indicate that, on average, patients experienced an 
improved sleep quality on rhGH treatment, as scores were below 5, the cut-off for 
impaired sleep quality. In particular, 3/6 patients went from a score above 5 to a 
score below 5. No difference was observed for the scores obtained for the 
component of the questionnaire focusing on daytime sleepiness. 
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Quality of life 
AGHDA scores in both sessions are available for 8 patients.  Global scores were 
significantly lower, i.e. improved, after 4 months of rhGH s.c. compared to placebo 
(8.82.5 vs 4.81.6, p=0.02 by paired Wilcoxon test). Ratings for the tiredness were 
also lower (0.040.03 vs 0.370.12, p=0.06 by paired Wilcoxon test). Furthermore, 
only 2/8 patients reported tiredness-related complaints at the end of the rhGH 
period, vs 5/8 after placebo. Fig. 20 describes the differences between the 2 sessions 
in the single domains for both age groups: scores improved in all domains, except 
for the domain “social isolation” in older patients, but the differences failed to reach 




Fig. 20: Differences (mean+SEM) in quality of life scores for the five domains of the QoL-AGHDA 
scale between placebo and rhGH for the younger (n=4) and older (n=4) GHD patients. Negative 





The present study, performed in a large group of adult GHD patients individually 
matched for gender, age and BMI with control subjects, indicates that GHD due to a 
confirmed or likely primary pituitary defect is associated with an excess of high 
intensity SWS, poor subjective sleep quality and daytime sleepiness. Furthermore, 
quality of life appeared impaired in these subjects at baseline, consistent with what 
is reported in literature: several studies have shown that aGHD patients complain of 
an impaired quality of life, and in particular of tiredness and low energy levels that 
significantly impact their daily life 30, 32-38. 
Excessive amounts of SWS represent an unusual form of sleep disturbance as the 
vast majority of sleep disorders are characterized by reduced, rather than enhanced, 
SWS. However, a relatively high duration of SWS (29% of total sleep time on 
average) was also reported in middle-aged GHD patients 162. Furthermore, a recent 
study performed in women with GHD due to Sheehan’s syndrome also found a 
longer SWS duration in patients compared to controls matched for age and BMI 158.  
In our study, the enhancement of EEG power in adult GHD patients was specific to 
the delta and theta ranges, as alpha power was similar in patients and controls. 
GHRH has been extensively documented as having a stimulatory effect on SWS 
and delta activity 111-114, 117. Furthermore, functional and anatomical evidence for a 
role of GHRH in the regulation of NREM sleep was obtained recently 108: indeed, 
the i.c.v. administration of GHRH to male adult rats produced an increase in NREM 
duration and SWA, as well as an activation of GABAergic neurons in sleep-active 
areas of the hypothalamus. One possible mechanism underlying the enhancement of 
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SWS and delta activity observed in GHD patients with no evidence of hypothalamic 
involvement could therefore be the lack of negative feedback regulation of GHRH 
by circulating GH, with a subsequent exaggeration of the stimulatory effect of 
GHRH on delta activity. Consistent with this putative mechanism, upregulation of 
hypothalamic GHRH activity, due to the absence of inhibitory control by GH, 
associated with increased amounts of NREM sleep has indeed been demonstrated in 
the spontaneous dwarf rat, an animal model of GHD due to a mutation of the GH 
gene 106, 170. Conversely, mice and rats with nonfunctional GHRH receptor (lit/lit 
mice and dw/dw rats) have lower amounts of spontaneous NREM sleep than wild 
types 104-105. A reduction in the inhibitory control of hypothalamic GHRH by GH 
might contribute to an incomplete inhibition of SWS generating mechanisms during 
wake as well as during sleep and result in daytime sleepiness. In all our pituitary 
GHD patients, tiredness was the most consistent complaint on the QoL-AGHDA 
scale and was correlated with daytime sleepiness as assessed by a validated 
questionnaire that is not specific of GHD. Among our younger patients, those with 
higher amounts of SWS tended to have higher tiredness scores in the QoL-
AGHDA. While these associations do not indicate causality, they suggest that sleep 
disturbances may contribute to daytime sleepiness and to tiredness complaints. 
Our findings are at variance with those reported 20 years ago in eight subjects with 
isolated GHD 159: the authors observed a decrease in SWS duration and delta 
activity in their patients. In this study, controls were matched for sex and age, but 
not for BMI. Bedtimes and sleep periods were not reported, activity during waking 
hours was not controlled and daytime naps were not prohibited. Total sleep time 
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was surprisingly long in patients, ranging from 7h45 to 11h44 with a median of 
nearly 9 hours. Extended bedtimes and naps generally result in a shift of NREM 
sleep towards lighter stages 71 which could explain the discrepancy with our 
findings. More recently, sleep profiles in a group of patients with adult onset GHD 
were reported to be comparable to a non-specified and non-individually matched 
healthy control group from the literature 161. Because of the high variability, 
especially with gender and age, of sleep characteristics among normal individuals, 
this study design was unlikely to detect differences between GHD patients and 
controls.  
In remarkable contrast to findings in the two groups of patients in whom there was 
no evidence for a supra-pituitary involvement in the etiology of GHD, the patients 
with hypothalamic GHD had shallow non-REM sleep with markedly lower delta 
power than their controls, consistent with reduced GHRH activity. While these 
limited results await confirmation in a larger group of patients, they are consistent 
with a central role of GHRH activity in modulating sleep quality in GHD. Of note, a 
marked decrease in SWS duration was reported in children with psychosocial 
dwarfism, in whom the origin of the GH deficiency is thought to be hypothalamic in 
origin 171-172. When re-evaluated after a period of separation from their family, these 
children exhibited a recovery of GH secretion and the normalization of SWS 
duration 171.  
Finally, delta activity results in our patients with pituitary defects and possible 
hypothalamic involvement were intermediate between those of pituitary and 
hypothalamic GHD patients, consistent with a mixed etiology of GHD.  
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 The impact of rhGH replacement on sleep architecture and quality was evaluated 
after 4 months treatment, and a significant reduction in sleep duration was 
observed. This is unlikely to be due to an order effect or to seasonality, as placebo 
and rhGH were administered in a randomized cross-over fashion and the patients 
were studied all year long. The underlying change in sleep architecture was 
different in younger and older patients, as younger patients displayed a decrease in 
SWS, while in older adults SWS was preserved at the expense of the shallower 
stages of NREM sleep (stages I and II). Similarly, delta activity was lower after 
treatment, mostly in younger subjects. 
Results published in literature about the effects of rhGH replacement on sleep in 
adult GHD patients are inconclusive. SWS duration was reported to be unchanged 
after 6 months on rhGH in young adult patients with isolated GHD, compared to 
baseline 159. Another group found a decrease in SWS duration in middle-aged 
patients with GHD of variable etiology after 6 months of rhGH withdrawal 160. 
Several authors report no impact of replacement therapy on sleep parameters, 
compared to placebo 158, 161-162. However, none of these reports took the impact of 
age into account, when the age range of the patients studied spanned from 21 to 73 
years. 
 
Consistent with literature, the impairment in QoL was at least in part reversible with 
rhGH treatment: our patients obtained lower, i.e. improved, scores in the QoL-
AGHDA questionnaire after 4 months treatment.  The physiologic basis of the 
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improved well-being induced by rhGH treatment has not been fully elucidated. 
However it is likely that GH exerts direct effects on the central nervous system, as 
demonstrated by the high density of GH receptors in the hippocampus and choroid 
plexus 173-174. Animal studies have shown that systemic GH administration 
influences the metabolism of monoamines in the brain 175. Moreover, an increase in 
cerebro-spinal fluid (CSF) beta-endorphin concentrations has been reported in adult 
GHD patients after treatment 176. Another group reported a decrease in CSF 
concentrations of homovanilic acid, a dopamine metabolite, similar to what is 
observed after successful pharmacologic treatment of depressive episodes 177. After 
rhGH replacement, the frequency of tiredness complaints decreased from 5/8 
patients to 2/8 compared to placebo. No association was observed between tiredness 
scores and sleep parameters, however the number of patients for whom data is 
available is limited (n=8). Subjective sleep quality was also improved by rhGH, as 
shown by the decrease of PSQI scores below the cut-off for impaired sleep quality; 
however the difference in scores was not significant and no correlation was 
observed between QoL-AGHDA tiredness scores and PSQI daytime sleepiness 
score, probably due to a lack of statistical power. To our knowledge, only one study 
evaluated subjective ratings of sleep quality in aGHD patients (n=12) 174: using the 
PSQI before and after 3 months treatment, the authors observed an improvement in 
the global score, the sleep quality and sleep latency scores but not daytime 
sleepiness. Unfortunately, sleep was not monitored in this study.  
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Older adults with pituitary GHD had less REM sleep than their controls. This loss 
of REM sleep, possibly due to GH deficiency 100-101, 152, 178, could be involved in the 
emergence of memory problems which were reported more frequently by older 
patients compared to their controls. There is indeed a growing body of evidence 
linking REM sleep and memory 179-180. Older adults with pituitary GHD also had 
more sleep fragmentation in the later part of the night and obtained less total sleep 
time than control subjects. While increased number and duration of awakenings, 
decreased total sleep time and decreased amounts of REM sleep are typical of 
normal adults in late life 42, pituitary GHD appears associated with an exacerbation 
of these sleep disturbances, suggestive of a more rapid senescence of sleep-
regulating mechanisms in the absence of GH. The combination of increased 
duration and intensity of SWS in the early part of the night with increased sleep 
fragmentation in the later part of the night represents a peculiar sleep disorder as 
higher levels of SWS are generally associated with more consolidated sleep.  
 
Nearly all GHD patients in our study received chronic replacement therapy 
(including hydrocortisone/cortisone acetate, L-thyroxine and sex steroids) to correct 
associated pituitary hormonal deficits. The substitution dose of glucocorticoid in 
some cases exceeded the normal endogenous cortisol secretion. However, the daily 
substitution dose (mean ± SEM) averaged 12.0±0.7 mg hydrocortisone per m2 of 
body surface area (considering that 25 mg cortisone acetate is equivalent to 15 mg 
hydrocortisone). This dose is quite in agreement with current recommendations 181. 
The rationale for administering somewhat higher hydrocortisone amounts than the 
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normal endogenous secretion is that the absorption is never 100%, and quite 
variable from one patient to another, and that oral administration schedule cannot 
mimic the physiological pattern of hormonal secretion: the morning dose is given 
when the patient wakes up, i.e. several hours after the onset of the endogenous 
circadian rise of cortisol in normal subjects. Thus, despite appropriate replacement 
therapy, patients with primary adrenal insufficiency or with adrenal insufficiency 
secondary to a primary pituitary defect are likely to have supra-normal nocturnal 
CRH levels, while patients with adrenal insufficiency secondary to a hypothalamic 
defect will have low CRH levels.  
Since CRH has been reported to inhibit SWS 182, elevated nocturnal levels of CRH 
in GHD patients with primary pituitary defects would favor a decrease of SWS, i.e. 
the opposite of what was observed.  Thus, it is unlikely that glucocorticoid 
replacement therapy would be responsible for the higher amounts of SWS observed 
in our patients when compared to controls. On the other hand, CRH is a well-
documented arousal factor that promotes wakefulness. Thus, elevated nocturnal 
levels of CRH in our patients could have promoted an increase in wake after sleep 
onset. Therefore, we cannot exclude that increased durations of wake in our patients 
with GHD of primary pituitary origin could be partly related to elevated CRH 
levels. 
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CONCLUSION   
In conclusion, the present findings indicate that GHD may be associated with major 
sleep alterations, and suggests that “tiredness”, a major QoL complaint in GHD, 
may reflect poor sleep quality and daytime sleepiness. The sleep phenotype of GHD 
may be dependent on its etiology. In particular, patients with GHD of pituitary 
origin appeared to have an increased duration of SWS and enhanced SWA 
compared to age, gender and BMI-matched controls. These results are compatible 
with the hypothesis of a higher endogenous GHRH tone in these patients, as GHRH 
has been shown to enhance SWS and SWA. Conversely, patients with GHD of 
hypothalamic origin displayed lower SWA levels, although these findings need to 
be replicated in a wider population. Age-dependent differences in sleep structure 
were observed, and the effects of aging on sleep (sleep fragmentation, lower sleep 
quality, decreased REM sleep duration) appeared to be exacerbated in older GHD 
patients.  Recombinant human GH treatment administered for 4 months appears to 
reverse some of the alterations observed in the macro- and micro-architecture of 
sleep, which likely contributes to the improved well-being reported by patients.  
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Appendix A: Quality of life Assessment of Growth 























Appendix C: Karolinska Sleep Log 
 
KAROLINSKA SLEEP LOG 
Complete in morning within one hour of awaking: 
1.  At what time did you go to bed and turn the light off last night? _____PM or AM 
2.  At what time did you wake up this morning? _____PM or AM 
3.  How long did you sleep? _____hours and _____minutes 
4.  How long did it take you to fall asleep? _____hours and_____minutes 
5.  How many awakenings did you have last night? _____ 
6.  How many total minutes were you awake after falling asleep last nigh
 _____minutes (Don't include time in bed before falling asleep) 
 
Circle one per question only: 
7. How did you sleep?  
1  2   3   4   5  
Very poorly             Very well 
8.  Did you feel refreshed after you arose this morning? 
1  2   3   4   5  
Not at all           Completely  
9.  Did you sleep soundly? 
1  2   3   4   5  
Very Restless        Very Soundly 
10.  Did you sleep throughout the time allotted for sleep? 
1   2   3   4  5  
Woke up much        Slept through 
 too early         the night 
11.  How easy was it for you to wake up? 
1   2   3   4  5  
Very Easy        Very Difficult 
12.  How easy was it for you to fall asleep? 
1   2   3   4  5  
Very Easy        Very Difficult 
13.  How much did you dream last night? 
1   2   3   4  5  
None         Very Much 
